SCHEMBL14719569

SCHEMBL14719569

COc1cc(N2CC(N(C)C)C2)c(Nc2nccc(-c3cn(C)c4ccccc34)n2)cc1N

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MKNK1 Q9BUB5 1/20 0.61
MKNK2 Q9HBH9 1/20 0.61
EGFR P00533 19/20 0.59
MLNR O43193 1/20 0.51
KDM1A O60341 1/20 0.51
ABCB11 O95342 1/20 0.51
ERBB2 P04626 1/20 0.51
INSR P06213 1/20 0.51
CHRM2 P08172 1/20 0.51
HTR1A P08908 1/20 0.51
ADORA3 P0DMS8 1/20 0.51
DRD2 P14416 1/20 0.51
NQO2 P16083 1/20 0.51
ADRA2C P18825 1/20 0.51
DRD1 P21728 1/20 0.51
ERBB3 P21860 1/20 0.51
SLC6A2 P23975 1/20 0.51
HTR2A P28223 1/20 0.51
HTR2C P28335 1/20 0.51
ADORA2A P29274 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30108160 0.94 MKNK1 (0.61) MKNK1MKNK2EGFRMLNRKDM1A
SCHEMBL14663274 0.94 MKNK1 (0.61) MKNK1MKNK2EGFRMLNRKDM1A
SCHEMBL29232101 0.94 EGFR (0.58) MKNK1MKNK2EGFRMLNRKDM1A
SCHEMBL30956832 0.94 EGFR (0.58) MKNK1MKNK2EGFRMLNRKDM1A
SCHEMBL29974314 0.89 EGFR (0.59) MKNK1MKNK2EGFRMLNRKDM1A
SCHEMBL14663290 0.89 EGFR (0.59) MKNK1MKNK2EGFRMLNRKDM1A
SCHEMBL14719543 0.89 EGFR (0.59) MKNK1MKNK2EGFRMLNRKDM1A
SCHEMBL30956837 0.89 EGFR (0.59) MKNK1MKNK2EGFRMLNRKDM1A
SCHEMBL14719016 0.87 EGFR (0.72) MKNK1MKNK2EGFRKCNH2
SCHEMBL31367926 0.87 EGFR (0.72) MKNK1MKNK2EGFRKCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8946235-B2 2-(2,4,5-substituted-anilino) pyrimidine compounds ASTRAZENECA AB (SE) 2015-02-03 US disclosed
US-20130053409-A1 2-(2,4,5-SUBSTITUTED-ANILINO) PYRIMIDINE COMPOUNDS ASTRAZENECA AB (SE) 2013-02-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130053409-A1 2-(2,4,5-SUBSTITUTED-ANILINO) PYRIMIDINE COMPOUNDS EGFR, ERBB2, ERBB3 MKNK1 2749/4885MKNK2 2846/4885EGFR 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.